Google
STRO 株価分析 — Sutro Biopharma (Healthcare >> Biotechnology)
STRO に関するよくある質問
STROのROE（自己資本利益率）は？
Sutro BiopharmaのROEは229.64%です。
STROの配当利回りは？
Sutro Biopharmaの配当利回りは0.00%です。
STROの品質スコア（Quality Score）は？
当社のAIはSTROの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
STROは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
STROはどのセクターに属しますか？
Sutro BiopharmaはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
STRO AI Analysis Summary
Our AI summary for STRO: Sutro Biopharma (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 229.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 24.17
Price
-0.65
(-2.62%)
Day Change
|
|
|---|
STRO, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 24.17 |
| PBV / Sector |
-6.15 / 5.20
|
| Earning Per Share | -9.03 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
7.99 M
|
| Average 1W Daily Value |
4.62 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:32 |
| Symbol | STRO |
| Name | SUTRO BIOPHARMA |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 16.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 411.28 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 881 6500
Website: https://www.sutrobio.com
Employees: 133
Sector: Healthcare >> Biotechnology
Description: Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
